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Abstract
Background: Fibromyalgia (FM) is a heterogeneous syndrome and its classification into subgroups calls for broad-
based discussion. FM subgrouping, which aims to adapt treatment according to different subgroups, relies in part,
on psychological and cognitive dysfunctions. Since motor control of gait is closely related to cognitive function, we
hypothesized that gait markers could be of interest in the identification of FM patients’ subgroups. This controlled
study aimed at characterizing gait disorders in FM, and subgrouping FM patients according to gait markers such as
stride frequency (SF), stride regularity (SR), and cranio-caudal power (CCP) which measures kinesia.
Methods: A multicentre, observational open trial enrolled patients with primary FM (44.1 ± 8.1 y), and matched
controls (44.1 ± 7.3 y). Outcome measurements and gait analyses were available for 52 pairs. A 3-step statistical
analysis was carried out. A preliminary single blind analysis using k-means cluster was performed as an initial
validation of gait markers. Then in order to quantify FM patients according to psychometric and gait variables an
open descriptive analysis comparing patients and controls were made, and correlations between gait variables and
main outcomes were calculated. Finally using cluster analysis, we described subgroups for each gait variable and
looked for significant differences in self-reported assessments.
Results: SF was the most discriminating gait variable (73% of patients and controls). SF, SR, and CCP were different
between patients and controls. There was a non-significant association between SF, FIQ and physical components
from Short-Form 36 (p = 0.06). SR was correlated to FIQ (p = 0.01) and catastrophizing (p = 0.05) while CCP was
correlated to pain (p = 0.01). The SF cluster identified 3 subgroups with a particular one characterized by normal
SF, low pain, high activity and hyperkinesia. The SR cluster identified 2 distinct subgroups: the one with a reduced
SR was distinguished by high FIQ, poor coping and altered affective status.
Conclusion: Gait analysis may provide additional information in the identification of subgroups among
fibromyalgia patients. Gait analysis provided relevant information about physical and cognitive status, and pain
behavior. Further studies are needed to better understand gait analysis implications in FM.
Background
In clinical trials and observational research studies,
fibromyalgia (FM) is usually diagnosed according to
American College of Rheumatology (ACR) 1990 criteria
[1]. However, patients fulfilling the ACR classification
criteria for FM do not constitute a homogeneous group
and the classification of FM into different subgroups
calls for broad-based discussion. Strazt et al [2] sought
to identify different FM subgroups by distinguishing
between FM with and without depression. Turk et al [3]
showed that subgroups identified by cluster analysis,
based on the Multidimensional Pain Inventory (MPI),
could be applicable to FM patients; this subgrouping
was based on psychosocial and cognitive characteristics.
Giesecke et al [4] showed that the combination of these
two features and pain sensitivity indices best distin-
guished subgroups of FM patients. Using the MPI,
Thieme et al [5] identified three subgroups of FM
patients on the basis of anxiety and psychiatric
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signs and symptoms, Müller [6] found that primary FM
can be divided into four subtypes: sensitivity to pain,
comorbid pain-related depression, concomitant depres-
sion, and FM due to somatization. Recently, De Souza
et al [7] featured two distinct subgroups using the Fibro-
myalgia Impact Questionnaire (FIQ): one was character-
ized by low anxiety levels, depression and morning
tiredness while the other was characterized by elevated
pain levels, fatigue, morning tiredness, stiffness, and
depressive symptoms. Using the Medical Outcomes
study 36-item Short Form Health Survey (SF-36),
Oswald et al [8] detected two subgroups: the first one
demonstrated psychological dysfunction, whilst the sec-
ond achieved normal psychological scores. In a large
survey, Wilson et al. [9] identified 4 subgroups of FMS
patients by means of a cluster analysis based on 3 symp-
tom factor scores: musculoskeletal symptoms, other
physical symptoms, and cognitive/psychological symp-
toms. All mentioned studies illustrate the great interest
of clinicians, in daily practice, in recognizing homoge-
nous subgroups in FM to provide guidance for treat-
ment decisions. Furthermore, research is ongoing to
assess FM severity and subgrouping FM patients by
means of quantitative measurements. More recently,
Aparicio [10] found that handgrip was reduced in
women with FM (p < .001), and inversely related to FM
severity and symtomatology.
Gait analysis shows a growing interest in the neurop-
sychological domain, in particular with regard to cogni-
tion and dementia [11], as well as anxiety and
depression [12]. The importance of cognition for gait
became evident with the observation that frail or cogni-
tively impaired elderly people could no longer walk
while performing a secondary task such as talking [13].
Gait has to be considered as a cognitive function and
not as an automated motor task [14]. Walking at a self-
selected speed requires cognitive resources, particularly
executive function and attention [15]. Given that FM
patients have cognitive function impairment that could
mimic about 20 years of ageing [16] we hypothesized
that gait could be impaired in FM patients. Affect also
has to be taken into account; indeed, depression and
a n x i e t yh a v ean e g a t i v ei n f l u e n c eo ng a i t ,p o s s i b l yb y
reducing attention to gait control [17].
In a preliminary study, we showed that gait impair-
ment in FM patients affects walking speed and walking-
derived markers such as stride frequency (SF), stride
regularity (SR), and cranio-caudal power (CCP) which
measures the kinesia of the movement according to the
cranial-caudal axis [18]. Furthermore, Heredia Jiménez
[19] found a significant difference between FM women
and control groups as regard spatial-temporal para-
meters of gait. In addition, correlations were found
between FIQ and spatial-temporal parameters of gait in
FM [19]. Therefore, we decided to undergo a case-con-
trol observational study on the interaction between FM
and gait in primary non-depressed FM patients without
any neurological treatment.
Our study aimed at characterizing gait disorders in
primary FM patients, looking for correlations between
gait markers and main FM features, and subgrouping
FM patients according to gait markers.
Methods
Study Design
This multicenter study was an exploratory, observational
open trial enrolling outpatients with primary FM and
healthy control subjects matched for age, height, and
weight. The one-to-one matching was realized by each
participating center. Ethics approval for this study was
obtained from the Human Ethics Committee of Nantes
University. All participants provided informed written
consent according to Helsinki declaration.
Study selection criteria
Healthy control subjects and patients were women aged
20 - 55 years able to walk 40 meters without assistance.
Healthy control subjects, if possible without any conco-
mitant medications, underwent a complete physical
examination. Patients with primary FM were recruited
according to ACR criteria. All of them had achieved an
average pain visual analogue score (VAS) of at least 40
on a scale of 0-100 mm, over the past week. They pre-
sented non-major depression according to the Mini-
International Neuropsychiatric Interview (MINI) [20].
Patients and controls with any of the following condi-
tions were excluded from the study: current or past car-
diovascular, pulmonary, neurological, rheumatologic,
endocrine, digestive or renal diseases; current systemic
infection; active cancer; and any history of/or existing
musculoskeletal disorders that could induce walking dis-
ability such as obesity (BMI > 30 kg/m
2), pregnant or
nursing women, or current psychiatric illnesses.
A routine work-up was performed at a central labora-
tory for all FM patients. Normal results constituted one
of the study inclusion criteria.
Study procedure
Data from a previous study [18] were used to calculate
the study power and the sample size. Gait markers dif-
fered considerably and were of clinical value in 14 FM
patients and 14 matched controls. Thus a sample size of
22 subjects in each group would provide statistical
power of > 0.95 with an alpha level of 0.05 to assess
p h y s i c a lf u n c t i o n sb yg a i ta n a l y s i si nF Mp a t i e n t sa n d
matched control subjects. No information was available
for the subgrouping of patients by gait analysis. Based
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controls. Study participants were screened/selected at
the time of a first visit (V1). Baseline assessments and
gait tests were realized at the second visit (V2), which
took place between one and four weeks later, depending
on the wash-out period needed for discontinuing central
nervous system (CNS) active drugs such as antidepres-
sants, antiepileptics, mood stabilizers, centrally acting
muscle relaxants, hypnotics, and analgesics type II or III.
Patients’ consent for drugs withdrawal was included in
their informed written consent. When patients experi-
enced an exacerbation of their FM pain severe enough
to require additional analgesia, paracetamol was allowed
as a rescue analgesic. Likewise, low doses of benzodiaze-
pines were allowed in case of anxiety.
Assessment tools
At V1, demographic data, exercise status, lifestyle, physi-
cal examination, vital signs and patients’ biological tests
were obtained. In addition, three psychological assess-
ments were carried out: the MINI, the State-Trait Anxi-
ety Inventory (STAI) and the Beck Depression Inventory
(BDI). Only certain parts of the MINI questionnaire were
used, particularly those exploring major depression, gen-
eralized anxiety, panic disorder, agoraphobia, social pho-
bia, obsessive compulsive disorder, post-traumatic
syndrome, alcohol and substances abuse and psychotic
disorders [20]. The STAI was used to assess state and
traits of anxiety [21]. The BDI was used to quantitatively
assess depression symptoms of patients [22]. Pain during
the previous week was evaluated at V1 and V2 by means
of the 100-mm VAS pain score. VAS at V1 and V2 were
similar so we referred to VAS at V1. Baseline assessments
included the Short Form McGill Pain Questionnaire (SF-
MPQ) [23]. The Coping Strategies Questionnaire (CSQ)
was used to assess patient’s strategies to cope with
chronic pain, and the efficacy of these strategies in con-
trolling pain [24]. The CSQ assessed the use of 6 cogni-
tive coping strategies (diverting attention, reinterpreting
pain sensations, coping self-statements, ignoring pain
sensations, praying or hoping, catastrophizing) and 1
behavioral coping strategy (increasing activity level). Fati-
gue intensity was measured by the Chalder Fatigue Scale
(CFS) [25]. Sleep quality and disturbances were assessed
by the Pittsburg Sleep Quality Index (PSQI) [26]. The SF-
36, including both physical component summary (PCS)
and mental component summary (MCS), was utilized for
the assessment of health status, functional status and
quality of life [27]. The FIQ was used to assess the overall
symptomatology of FM patients [28].
Gait analysis
The gait analysis system (Locometrix™)i n c l u d e sa n
accelerometric sensor, a recording device and a
computer program for processing the acceleration sig-
nals. The sensor, composed of three accelerometers, is
incorporated into a semi-elastic belt, which is fastened
around the subject’s waist. One accelerometer is aligned
with the cranio-caudal axis of the body. A gait test was
performed during a stabilized walk at a self-selected
speed, which allowed obtaining stabilized gait measure-
ments. Patients and controls wore their usual walking
shoes. The duration of gait analysis was long enough to
include 19-21 gait cycles.
Gait markers
The analysis software allowed the characterization of
gait by measuring the following markers: walking
speed, SF, stride length, right and left step symmetry,
SR, and CCP. Walking speed is measured in meter per
second (m/s), and SF is the number of gait cycles per
second (Hertz (Hz)). Stride length is calculated from
the average speed divided by the SF (meter (m)). Right
and left step symmetry on vertical accelerations is an
index of overall symmetry (dimensionless). SR quanti-
fies the spatial-temporal similarity between successive
gait cycles, which is a measure of stride-to-stride varia-
bility (dimensionless). CCP (W/kg) measures the
amount of movement (magnitude and frequency) in
the cranio-caudal axis and can be considered as a mea-
surement of the kinesia [29].
Statistical analysis
The primary assessment was the quantitative evalua-
tion of gait markers. A preliminary single blind analy-
sis was performed as an initial validation of gait
markers. The statistician had to cluster all participants
(patients and controls, identities were coded) into FM
patients and control subjects using k-means cluster
analysis limited to two clusters. Then the descriptive
analysis was performed on each gait marker alone and
then by combining different markers in order to
improve the sensitivity or specificity i.e. the ability to
detect FM or controls. Comparisons between FM
patients and control subjects were made in an open
statistical analysis. The purpose was to quantify FM
patients according to psychometric, self-questionnaire
assessment and gait markers. Main outcomes were
obtained using all items, which differed significantly
between patients and controls without any center
effect. In addition, ROC curve analysis of gait markers
was performed. Finally, correlations between gait mar-
kers and main outcomes were calculated.
Thirdly, using the hierarchical cluster analysis and cal-
culating the Euclidian distances between groups accord-
ing to Ward, we described subgroups for each gait
marker and looked for significant differences in self
reported assessments.
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Population characteristics
Out of 132 subjects (73 FM patients and 59 controls)
eligible to be enrolled at V2, 104 (52 matched pairs)
completed the study according to the protocol. Table 1
shows that patients and controls characteristics at V1
were not statistically different except for professional
status, concomitant treatment, STAI-trait, and BDI.
The STAI-state was not different between patients and
controls. No pain was recorded in the control group.
Self-report measures at V2 are shown in table 2. The
variance analysis showed a center effect for physical
functions in FIQ (P < 0.05), and reinterpreting pain
sensations in CSQ (P < 0.05). These 2 items were
therefore excluded from the statistical analysis. Gait
markers in patients and controls, and variance analysis
of the center effect are shown in table 3. Consequently,
3 gait markers were selected for statistical analysis: SF,
SR and CCP. ROC curves confirmed the utility of gait
markers in the identification of patients (area under
the curve for SF, SR and CCP were 0.740 (0.044),
0.678 (0.052) and 0.690 (0.053), respectively). The
blind cluster analysis showed that SF was the most dis-
criminating marker among patients and controls (38/
52 (73%)).
Correlation analysis
No correlation was found between gait markers and SF-
MPQ, CFS, PSQI, SF-36. A tendency to correlation was
shown between SF-36 PCS and SF (P = 0.06). VAS was
negatively correlated to CCP (r = -0.33, P =0 . 0 1 ) .T h e
FIQ score was negatively correlated to SR (r = -0.34, P
= 0.01), and had a tendency to correlate with SF (r =
-0.26, P = 0.06). Among CSQ items, only diverting
attention and coping statement were positively corre-
lated to SF. Coping self statement and catastrophizing
were positively and negatively correlated to SR, respec-
tively (Table 4).
Cluster analyses
The cluster analysis of SF (Table 5) allowed the identifi-
cation of 3 distinct subgroups with an Euclidian dissimi-
l a r i t ys c a l eo f1 7( Fr a t i o=7 6 ,P =0 ) .T h eS Fm e a n
standard error (SE) for subgroups I (n = 9), II (n = 24)
and III (n = 19) was 1.04 (0.01), 0.94 (0.007), and 0.86
(0.008), respectively. No differences were observed for
BDI, STAI-trait, SF-MPQ, CSQ, CFS, PSQI, SF-36 MCS
subscore and SR. The following differences have been
observed between these 3 subgroups: VAS score was
significantly lower in subgroup I than in subgroup II (P
= 0.01). FIQ score was significantly lower in subgroup I
compared to subgroups II and III (P = 0.004). PCS sub-
score of SF-36 was significantly higher in subgroup I
than group III (P = 0.04), and CCP score was signifi-
cantly higher in subgroup I than the other two sub-
groups (P = 0.0002).
Cluster analysis of SR (Table 6) allowed the identifica-
tion of 2 distinct subgroups with a dissimilarity scale of
17 (F ratio = 88, P = 0). The mean SR ± standard error
for subgroup I (n = 32) was higher than for subgroup II
(n = 20) 291 ± 4 versus 229 ± 5. No difference was
observed for VAS, SF-MPQ, CFS PSQI, SF-36, SF and
CCP. Patients with low SR were more depressed (P =
0.03) and showed more anxiety traits (P =0 . 0 3 )t h a n
patients with normal SR. Furthermore, patients with low
SR had reduced coping strategies such as self-statement
(P = 0.003) as well as greater tendency towards catatro-
phizing (P = 0.002). Finally, low SR was associated with
higher FIQ score (P = 0.02).
Cluster analysis of CCP values (results not shown)
allowed the identification of 3 distinct subgroups with
a dissimilarity scale of 17 (F ratio = 184, P =0 ) .T h e
mean CCP (SE) was higher in subgroup II (n = 8) than
subgroups I (n = 24) and III (n = 20): 5.31 (0.18) ver-
sus 1.41 (0.10) and 2.92 (0.1), respectively. On the
other hand, the multivaried analysis of these sub-
groups, based on main outcome measurements,
showed no differences between the 3 subgroups, except
for VAS that was significantly low in the subgroup II
Table 1 Characteristics of the study population at the
time of the screening visit
Measurements FM patients
n=5 2
Controls
n=5 2
P
Age, mean (SD) years 44.1 (8.1) 44.5 (7.3) 0.59
Height, mean (SD) cm 165 (5.8) 164 (6.4) 0.35
BMI, mean (SD) k/m
2 24.2 (4.1) 23.8 (4.4) 0.95
Marital Status 0.57
Married, n 33 38 NS
Other situations, n 19 14 NS
Education level 0.97
Primary education, n 2 2 NA
Secondary education, n 27 26 0.98
Higher education, n 23 24 0.98
Professional Activity, n 50 32 < 0.0001
Physical exercise, n 32 32 NS
Concomitant treatment, n 37 17 < 0.0001
BDI, mean score (SD) 15.8 (8.2) 3.8 (3.7) < 0.0001
STAI-State, mean score (SD) 37.3 (13.6) 29.6 (8.4) 0.16
STAI-Trait, mean score (SD) 44.1 (12.6) 35.6 (9.0) 0.02
VAS weekly, mean score (SD) 63.4 (21.5) 2.8 (7.8) 0.0001
Tender points, mean (SD) 16.2 (2.1) 0 NA
Pain duration, mean (SD) years 7.3 (6.6) 0 NA
NS = not stated; NA = not applicable; BDI = Beck Depression Inventory; STAI =
State-Trait Anxiety Inventory; VAS = Visual Analog Scale.
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74.6, respectively, P =0 . 0 0 6 .
Discussion
Patients
Only patients with primary FM were enrolled in the
study. Excluded patients were those with secondary
fibromyalgia in relation to an underlying disease such as
rheumatoid processes that could interfere with gait ana-
lysis. All study patients fulfilled the ACR criteria and
presented primary FM without major depression based
on the MINI questionnaire. However, 3 patients had
BDI scores reaching the value of severe depression [30].
This could be due to the fact that total BDI score may
give a misleading impression of the nature and degree
of affective disturbances in chronic pain, in relation with
BDI items assessing physical symptoms [31]. In our
study, we found a strong positive correlation between
BDI scores and somatic disturbances subscores. Accord-
ing to FIQ values few of our patients have severe FM
w i t haF I Qs c o r eo v e r7 0[ 3 2 ] .T h i sf i n d i n gc o u l db e
related to the absence of patients with major depression
(according to the MINI) as well as obese patients.
Depression constitutes one of the items measured by
the FIQ. Obesity may contribute to the severity of FM
as it reduces physical functioning and increases fatigue
[33], which are a part of some FIQ items. However, no
significant association between FM symptoms and obe-
sity was found in the same study. On the other hand,
obesity was associated with significant gait abnormalities
such as lower SF (p = 0.01), decreased SR (p < 0.001),
and reduced CCP (p < 0.001) in comparison with con-
trols (unpublished data). So FM obese patients were
excluded in this study.
Gait assessment
Ambulatory gait analysis has been demonstrated as a
reliable method in clinical practice for outpatients, [34].
Such gait analysis systems has been designed for clini-
cians looking for quantifying gait abnormalities, to grade
gait disorder-related disability, and to provide a better
pathology’s understanding for tailored treatment. This
way of thinking about gait analysis was emerged from
previous researches conducted in gait analysis
Table 2 Self-report measurements at the time of baseline visit
Measurements FM patients
n=5 2
Controls
n=5 2
P
VAS weekly, mean score (SD) 70 (18.1) 3.6 (9.7) < 0.0001
SF-MPQ, mean score (SD) 24.5 (9.4) 1.3 (3.3) < 0.0001
FIQ, mean score (SD) 56.6 (15.1) 4.5 (8.3) < 0.0001
CSQ
Diverting attention, mean score (SD) 16 (7.4) 10 (9.3) 0.008
Reinterpreting pain sensations, mean score (SD) 9.2 (7.7) 5.5 (6.4) 0.01
Coping self-statement, mean score (SD) 24.2 (7.1) 16.5 (10.6) 0.0009
Ignoring pain sensation, mean score (SD) 15.6 (8.1) 13.5 (9.3) 0.48
Praying and hoping, mean score (SD) 12.1 (7.2) 6.8 (7.5) 0.0002
Catastrophizing, mean score (SD) 14.5 (9.2) 4.6 (5.7) < 0.0001
Increasing activity level, mean score (SD) 18.8 (6) 14.3 (9.6) 0.09
CFS, mean score (SD) 20.8 (5.6) 11.3 (2.2) < 0.0001
PSQI, mean score (SD) 11.3 (4.3) 4.3 (2.7) < 0.0001
SF-36
Physical component summary, mean score (SD) 34 (7.5) 56 (4) < 0.0001
Mental component summary, mean score (SD) 40.6 (10.5) 50.9 (6.7) 0.002
VAS = Visual Analog Scale; SF-MPQ = Mc Gill Pain Questionnaire; FIQ = Fibromyalgia Impact Questionnaire; CSQ = Coping Strategies Questionnaire; CFS =
Chalder Fatigue Scale; PSQI = Pittsburg Sleep Quality Index; SF-36 = Short Form 36 items Medical Outcomes Study Questionnaire
Table 3 Gait markers, center effect, and ROC curve analysis in the study population
Gait markers Patients
n=5 2
Controls
n=5 2
P Center effect Area under the ROC curve
Walking speed, mean (SD) (m/s) 1.18 (0.19) 1.32 (0.17) 0.00007 P < 0.03 ND
Stride Frequency, mean (SD) (Hz) 0.93 (0.07) 0.99 (0.07) 0.000008 P = 0.36 0.740 (0.044)
Symmetry, mean (SD) (WD) 213 (39) 227 (38) 0.067 P < 0.03 ND
Stride regularity, mean (SD) (WD) 267 (38) 293 (39) 0.0007 P = 0.10 0.678 (0.052)
Cranio-caudal Power, mean (SD) (W/Kg) 2.59 (1.45) 3.63 (1.51) 0.0005 P = 0.12 0.690 (0.053)
ND = not done; WD = without dimension
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analysis has to be considered as a complementary exam.
The gait analysis system, gait tests and derived markers
have been previously validated [36,37]. Walking at self-
selected overground speed is the gold standard of gait
analysis [38]. SF expresses basic rhythmic stepping while
SR expresses gait unsteadiness according to temporal
and dynamic parameters, which is referred to as gait
variability [39]. CCP, previously studied in Parkinson’s
disease (PD), is correlated to motor score and proposed
as a measurement of kinesia [29].
Gait markers in fibromyalgia
In our study, SF revealed to be the best gait marker dif-
ferentiating FM patients from controls allowing the
identification of 3 out of 4 subjects in each group. This
finding raises the question of the importance of SF in
FM, and its significance in terms of underlying mechan-
ism, contrary to PD patients in whom SF remained
unaltered [40]. In addition, SF in our study was corre-
lated to diverting attention and coping self assessment,
which are associated with high physical and low psycho-
social disability levels [41]. Finally, we found a weak cor-
relation between SF, FIQ and physical component of SF-
36. These results suggest that SF may be of interest in
assessing the physical component of FM.
In our study, SR was strongly correlated to FIQ and to
catastrophizing that is a major CSQ item. In FM,
catastrophizing is a main cognitive factor, and can pro-
spectively predict high level of pain and depression, and
low quality of life [41]. SR measures the unsteadiness of
gait, and it has been linked to many neurological dis-
eases such as PD [29], Alzheimer’s disease [42], and pre-
clinical stages of dementia [12]. Interestingly, a recent
investigation disputed the concept of automatic regula-
tion and suggested that stride time variability is related
to specific cognitive processes, namely executive func-
tion and attention [39]. Therefore, SR could be sug-
gested as a measurement of cognitive reserve in FM.
CCP, which measures kinesia, was found to be the
only correlation in our study between pain and gait ana-
lysis. In fact, CCP measurement reflected the fear of
pain (kinesiophobia), which is a classic behavior in FM
patients leading to a reduction in their movements [43].
This result highlights the significance of gait analysis
and pain behavior assessment in chronic painful condi-
tions previously described in patients with lower back
pain [44]. Kinesia evaluation by means of CCP measure-
ment could be a promising area of research in the field
of pain behavior management.
Gait markers were not correlated to fatigue, sleep dis-
orders or mental component of SF-36. This result has
to be discussed according to the gait test that was pri-
marily designed to analyze gait in the basal condition at
a self-selected speed. Additional components to the gait
test could thus be suggested such as 6-minute walk test
Table 4 Correlations between gait markers and main outcomes measurements
Outcomes measurements Gait markers
Stride frequency Regularity CCP
VAS weekly pain r = -0.33, P = 0.01
FIQ score r = -0.26, P = 0.06 r = -0.34, P = 0.01
CSQ score
Diverting attention r = 0.42, p = 0.002
Coping self-statement r = 0.28, P = 0.04 r = 0.31, P = 0.03
Catastrophizing r = -0.27, P = 0.05
SF-36 (PCS) r = 0.27, P = 0.06
CCP = Cranio-caudal Power; VAS = Visual Analog Scale; FIQ = Fibromyalgia Impact Questionnaire; CSQ; Coping Strategies Questionnaire; SF-36 (PCS) = Short Form
36 items Medical Outcomes Study Questionnaire- physical component summary
Table 5 Cluster analysis of stride frequency and variance analysis of main outcomes measurements in fibromyalgia
patients
Subgroup I
n=9
Subgroup II
n=2 4
Subgroup III
n=1 9
Comparison of subgroups F ratio P
SF, mean (SE) (Hz) 1.04 (0.03) 0.94 (0.02) 0.86 (0.02) I, II ≠ III 76 0
VAS weekly, mean score (0 - 100) 56.9 (12.9) 76.9 (7.1) 67.5 (8.1) I ≠ II 4.99 0.01
FIQ, mean score (0 - 100) 42.0 (10.6) 59.6 (5.8) 59.8 (6.6) I ≠ II & III 6.20 0.004
SF-36 (PCS), mean score (0 - 100) 39.9 (5.8) 33.5 (3.0) 32.2 (3.4) I ≠ III 3.35 0.04
CCP, mean (W/Kg) 4.2 (1.0) 2.6 (0.5) 1.9 (0.6) I ≠ II & III 10.63 0.0002
SF = stride frequency; SE = standard error; VAS = Visual Analog Scale; FIQ = Fibromyalgia Impact Questionnaire; SF-36 (PCS) = Short Form 36 items Medical
Outcomes Study Questionnaire - physical component summary; CCP = Cranio-caudal power
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ders in FM patients.
Cluster analysis
The cluster analysis strengthened the clinical signifi-
cance of each gait marker. Cluster analysis of SF identi-
fied an interesting subgroup characterized by a normal
SF associated with low pain level (VAS), reduced overall
symptomatology (FIQ), high activity (PCS) and hyperki-
nesia. The two other subgroups with reduced SF were
characterized by high pain level, low activity and
hypokinesia.
Cluster analysis confirms the correlations observed in
the subgroup with low SR, characterized by reduced
self-statement, increasing catastrophizing, and high FIQ.
This subgroup was also distinguished by more anxiety
and depression. Therefore, one may raise the question
of possible overlap between the subgroup with low SR,
identified on the basis of gait analysis, and other sub-
groups distinguished by means of different cluster meth-
ods based on anxiety, depression and cognitive features.
Consequently, considering the important role of affect
and cognition in FM patients, one could suggest SR
measurement before initiating cognitive-behavioral
therapies in order to adapt treatment approaches to
patients’ characteristics [45]. Cluster analysis of CCP
enabled the identification of a subgroup with low pain
level and hyperkinesia. Our hypothesis is that each gait
marker is correlated to one of the major traits of FM
patients such as pain (CCP), physical activity (SF), and
catastrophizing (SR).
Clinical value
The three main gait markers (SF, SR, CCP) were corre-
lated to some major clinical characteristics of patients
(VAS, FIQ score, Coping self statement, Catastrophizing,
PCF from SF-36). Such statistical results are needed, but
are not sufficient for clinical applications. This point
received a first answer through Cluster analysis. Each
cluster analysis of gait markers provided distinct
subgroups in term of mean value of the gait marker
taken into account, but homogenous in term of clinical
characteristics. Furthermore a preliminary study showed
that the improvement of gait markers is of clinical sig-
nificance in FM patients after a 12-week rehabilitation
and exercise training program [46].
Study limitations
Our study has some limitations. The presence of a
center effect concerning some gait markers such as
step length and gait speed, on the one hand, and phy-
sical activity subscore of FIQ, on the other hand, did
not permit the determination of correlations between
these items. The reduced speed in FM [18,19] could be
more difficult to interpret because it is the product of
SF by SL. The assumption that SL is supraspinally con-
trolled by phasic output from basal ganglia to the sup-
plementary motor area should be discussed, not only
according to grading and subgrouping of FM but also
according to the disease’s underlying mechanisms.
Another limitation is the absence of FM patients hav-
ing major depression. Currently, it is demonstrated
that depression is associated with gait deterioration
and cognitive impairment [47]. Further studies are
required in order to better understand gait disorders in
FM patients with depression. As well, the exclusion of
obese patients from the study population could be
considered as a study limitation, however it is impor-
tant to take into account that the prevalence of obesity
varies greatly between the different studies according
to the area of the study. For instance, in North Amer-
ica a prevalence of 47% was reported [33] while in
North Europe the prevalence is only of 10%. [48].
Further limitations are related to sample characteris-
t i c s .O u rs t u d yi n v o l v e do n l yw o m e n ,s i n c et h eo c c u r -
rence of FM in men is fairly limited.
Conclusions
In conclusion, gait marker measurement, in particular
SF, SR, and CCP, could be of interest in subgrouping
Table 6 Cluster analysis of stride regularity and variance analysis of main outcomes measurements in fibromyalgia
patients
Subgroup I
n=3 2
Subgroup II
n=2 0
F ratio P
SR, mean (SE) (WD) 291.3 (8.4) 229.3 (10.8) 88 0
BDI, mean score (0 - 63) 13.8 (2.8) 19.0 (3.7) 5.35 0.03
STAI-Trait, mean score (20 - 80) 41.2 (4.4) 48.9 (5.7) 4.97 0.03
CSQ self-statement, mean score (0 - 36) 26.5 (2.4) 20.7 (3.1) 9.49 0.003
CSQ catastrophizing, mean score (0 - 36) 11.6 (3.1) 19.3 (4.0) 10.18 0.002
FIQ, mean score (0 - 100) 52.8 (5.2) 62.7 (6.8) 5.74 0.02
SR = Stride regularity; SE = standard error; WD = without dimension; BDI = Beck Depression Inventory; STAI = State-Trait Anxiety Inventory; CSQ = Coping
Strategies Questionnaire; FIQ = Fibromyalgia Impact Questionnaire
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Page 7 of 9FM patients, with no major depression. In our study, SF
was the most sensitive and specific gait marker for dis-
tinguishing FM patients from controls. High SF values
characterized a hyperkinetics u b g r o u po fF Mp a t i e n t s .
So, subgrouping FM patients on the basis of SF mea-
surement could facilitate the prescription of physical
activity for patients with normal SF, and incite clinicians
to prescribe a slowly progressive physical activity pro-
gram for those with reduced SF. SR allows the identifi-
cation of two subgroups, which were significantly
different in terms of coping, affective status, and overall
symptomatology (FIQ). Reduced SR values characterized
a subgroup of FM patients with poor affect and cogni-
tive abilities. SR measurement could therefore help in
the orientation of the behavioral therapy in this sub-
group of patients. Due to the strong correlation between
CCP and pain level, we suggest that CCP measurement
could be of interest in the assessment of pain behavior
among FM patients. Further studies are needed to assess
the interest of gait markers in the identification of sub-
groups of FM patients.
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